Nina Gulbrandsen

  • Associated research doctor; MD, PhD
  • +47 230 72 222
 

Original articles

Tangen JM, Tjønnfjord GE, Gulbrandsen N, Gedde-Dahl T, Stormorken E, Anderson K, Vo CD, Schjesvold FH, For Oslo Myeloma Center (2018)
Improved outcome in patients following autologous stem cell transplantation for multiple myeloma in south eastern Norway 2001-2010: a retrospective, population based analysis
BMC Cancer, 18 (1), 801
DOI 10.1186/s12885-018-4722-x, PubMed 30089450

Mellqvist UH, Gimsing P, Hjertner O, Lenhoff S, Laane E, Remes K, Steingrimsdottir H, Abildgaard N, Ahlberg L, Blimark C, Dahl IM, Forsberg K, Gedde-Dahl T, Gregersen H, Gruber A, Guldbrandsen N, Haukås E, Carlson K, Kvam AK, Nahi H, Lindås R, Andersen NF, Turesson I, Waage A, Westin J et al. (2013)
Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial
Blood, 121 (23), 4647-54
DOI 10.1182/blood-2012-11-464503, PubMed 23616624

Hjorth M, Hjertner Ø, Knudsen LM, Gulbrandsen N, Holmberg E, Pedersen PT, Andersen NF, Andréasson B, Billström R, Carlson K, Carlsson MS, Flogegård M, Forsberg K, Gimsing P, Karlsson T, Linder O, Nahi H, Othzén A, Swedin A, Nordic Myeloma Study Group (NMSG) (2012)
Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study
Eur J Haematol, 88 (6), 485-96
DOI 10.1111/j.1600-0609.2012.01775.x, PubMed 22404182

Nilsson-Ehle H, Birgegård G, Samuelsson J, Antunovic P, Astermark J, Garelius H, Engström LM, Kjeldsen L, Nilsson L, Olsson A, Skov-Holm M, Wallvik J, Gulbrandsen N, Hellström-Lindberg E (2011)
Quality of life, physical function and MRI T2* in elderly low-risk MDS patients treated to a haemoglobin level of ≥120 g/L with darbepoetin alfa ± filgrastim or erythrocyte transfusions
Eur J Haematol, 87 (3), 244-52
DOI 10.1111/j.1600-0609.2011.01654.x, PubMed 21623919

Waage A, Gimsing P, Fayers P, Abildgaard N, Ahlberg L, Björkstrand B, Carlson K, Dahl IM, Forsberg K, Gulbrandsen N, Haukås E, Hjertner O, Hjorth M, Karlsson T, Knudsen LM, Nielsen JL, Linder O, Mellqvist UH, Nesthus I, Rolke J, Strandberg M, Sørbø JH, Wisløff F, Juliusson G, Turesson I et al. (2010)
Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma
Blood, 116 (9), 1405-12
DOI 10.1182/blood-2009-08-237974, PubMed 20448107

Iversen PO, Wisløff F, Gulbrandsen N (2009)
Reduced nutritional status among multiple myeloma patients during treatment with high-dose chemotherapy and autologous stem cell support
Clin Nutr, 29 (4), 488-91
DOI 10.1016/j.clnu.2009.12.002, PubMed 20044183

Bird J, Behrens J, Westin J, Turesson I, Drayson M, Beetham R, D'Sa S, Soutar R, Waage A, Gulbrandsen N, Gregersen H, Low E, Haemato-oncology Task Force of the British Committee for Standards in Haematology, UK Myeloma Forum and Nordic Myeloma Study Group (2009)
UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS)
Br J Haematol, 147 (1), 22-42
DOI 10.1111/j.1365-2141.2009.07807.x, PubMed 19673884

Iversen PO, Ukrainchenko E, Afanasyev B, Hulbekkmo K, Choukah A, Gulbrandsen N, Wisløff F, Tangen JM (2008)
Impaired nutritional status during intensive chemotherapy in Russian and Norwegian cohorts with acute myeloid leukemia
Leuk Lymphoma, 49 (10), 1916-24
DOI 10.1080/10428190802339723, PubMed 18949615

Piehler AP, Gulbrandsen N, Kierulf P, Urdal P (2008)
Quantitation of serum free light chains in combination with protein electrophoresis and clinical information for diagnosing multiple myeloma in a general hospital population
Clin Chem, 54 (11), 1823-30
DOI 10.1373/clinchem.2008.106153, PubMed 18801937

Wisløff F, Gulbrandsen N, Hjorth M, Lenhoff S, Fayers P (2005)
Quality of life may be affected more by disease parameters and response to therapy than by haemoglobin changes
Eur J Haematol, 75 (4), 293-8
DOI 10.1111/j.1600-0609.2005.00509.x, PubMed 16146535

Waage A, Gimsing P, Juliusson G, Turesson I, Gulbrandsen N, Eriksson T, Hjorth M, Nielsen JL, Lenhoff S, Westin J, Wislöff F, Nordic Myeloma Study Group (2004)
Early response predicts thalidomide efficiency in patients with advanced multiple myeloma
Br J Haematol, 125 (2), 149-55
DOI 10.1111/j.1365-2141.2004.04879.x, PubMed 15059136

Gulbrandsen N, Hjermstad MJ, Wisløff F, Nordic Myeloma Study Group (2004)
Interpretation of quality of life scores in multiple myeloma by comparison with a reference population and assessment of the clinical importance of score differences
Eur J Haematol, 72 (3), 172-80
DOI 10.1046/j.0902-4441.2003.00195.x, PubMed 14962235

Hellström-Lindberg E, Gulbrandsen N, Lindberg G, Ahlgren T, Dahl IM, Dybedal I, Grimfors G, Hesse-Sundin E, Hjorth M, Kanter-Lewensohn L, Linder O, Luthman M, Löfvenberg E, Oberg G, Porwit-MacDonald A, Rådlund A, Samuelsson J, Tangen JM, Winquist I, Wisloff F, Scandinavian MDS Group (2003)
A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life
Br J Haematol, 120 (6), 1037-46
DOI 10.1046/j.1365-2141.2003.04153.x, PubMed 12648074

Review articles

Kvam AK, Fayers P, Hjermstad M, Gulbrandsen N, Wisloff F (2009)
Health-related quality of life assessment in randomised controlled trials in multiple myeloma: a critical review of methodology and impact on treatment recommendations
Eur J Haematol, 83 (4), 279-89
DOI 10.1111/j.1600-0609.2009.01303.x, PubMed 19558508

Theses

Gulbrandsen N (2006)
Health related quality of life and cost-utility in the treatment of multiple myeloma
In Series of dissertations submitted to the Faculty of Medicine, University of Oslo, Unipub, Oslo, no. 437, 1 b. (flere pag.)
BIBSYS 061837156

Page visits: 6524